DTIL

TentativeAI Memo

Precision BioSciences

As of 2026-09-30/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-30 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Year-end PBGENE-HBV clinical update • 2026-12-31

Base target: $6 / p=45% prob

Biggest risk

HBV evidence remains early and based on few patients; DMD has not reported initial safety data. Delays, adverse findings or greater spending could weaken the thesis and increase dilution risk.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The reported HBV biomarker findings could gain credibility with larger, durable follow-up data, while DMD dosing adds a second clinical program. Management expects cash to support both programs' data milestones through 2028 [#SEC-8K-2026-08-06] [#8-K-2026-08-24].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-30

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway depends on clinical spending and financing access
The reported HBV biomarker findings could gain credibility with larger, durable follow-up data, while DMD dosing adds a second clinical program.
Management expects cash to support both programs' data milestones through 2028 [#SEC-8K-2026-08-06] [#8-K-2026-08-24].

BearKey bullets

Cash declined during the first half of 2026; the stated runway partly assumes continued access to an at-the-market facility, creating dilution risk [#SEC-8K-2026-08-06].
First-in-human DMD safety, enrollment and subsequent efficacy remain unproven.
LNP-related hypotension occurred during HBV dose escalation; the company says mitigation measures improved it [#SEC-8K-2026-08-06].

WatchKey bullets

Year-end PBGENE-HBV clinical update

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $6 (p=45%)

Target spread vs base: +55% / -48%

Scenario probabilities

Bull Target: $9 (p=25%)Base Target: $6 (p=45%)Bear Target: $3 (p=30%)

Commentary

Company updates are constructive on trial execution, including August DMD first dosing, but the supplied evidence does not establish a sustained post-release price reaction or verified analyst revisions. Social, options, short-interest and employee-sentiment coverage is unavailable; the zero fields above indicate unavailable measurements, not neutral readings. The deterministic prior has turned negative since the June baseline, supporting a cautious monitoring view.

As of 2026-09-30 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

HBV evidence remains early and based on few patients; DMD has not reported initial safety data. Delays, adverse findings or greater spending could weaken the thesis and increase dilution risk.

Drivers

Scannable catalysts and supporting factors

Runway depends on clinical spending and financing access

Scenarios

Bull Target (Scenario probability)

$9 / p=25% prob

Base Target (Scenario probability)

$6 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Year-end PBGENE-HBV clinical update
Precision targets an ELIMINATE-B update by year-end 2026. Earlier biopsy and blood-biomarker findings support interest, but the small early-stage dataset leaves durability, safety and dose selection unresolved [#SEC-8K-2026-08-06].
Prob 65.00% • Move 18.00% • Priced-in 40.00%
EVENT2026-12-31
First FUNCTION-DMD safety data
The first PBGENE-DMD patient was dosed in August, and Precision expects initial Phase 1/2 safety data by year-end 2026. This is a trial-execution milestone, not yet evidence of clinical efficacy [#8-K-2026-08-24] company release.
Prob 60.00% • Move 15.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway depends on clinical spending and financing access
2027-06-30
June 30 cash, cash equivalents and restricted cash were $112.4 million, down from $137.2 million at year-end 2025. Precision expects runway through 2028, citing operating discipline and availability of its at-the-market facility; dilution remains a risk [#SEC-8K-2026-08-06] company earnings release.
Prob 65% • Move 8% • Priced-in 60%

Risks

Cash declined during the first half of 2026; the stated runway partly assumes continued access to an at-the-market facility, creating dilution risk [#SEC-8K-2026-08-06].
First-in-human DMD safety, enrollment and subsequent efficacy remain unproven.
LNP-related hypotension occurred during HBV dose escalation; the company says mitigation measures improved it [#SEC-8K-2026-08-06].
Small early-stage HBV dataset may not establish durable clinical benefit or an acceptable expansion dose.

Peers

Symbol	Summary
RGNX	Direct Duchenne indication comparator: REGENXBIO's RGX-202 is an AAV gene therapy with substantially more advanced clinical development. It helps frame DMD evidence and regulatory risk, but its stage and technology make it an unsuitable like-for-like valuation peer REGENXBIO update.
SLDB	Direct Duchenne development comparator: Solid BioSciences is studying the AAV-delivered SGT-003 gene therapy in clinical trials. Its microdystrophin approach differs from DTIL's gene editing, so trial-safety and enrollment comparisons are more useful than valuation multiples Solid BioSciences Q2 update.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-30

Loading AI feed…

Symbol

Summary

RGNX

Direct Duchenne indication comparator: REGENXBIO's RGX-202 is an AAV gene therapy with substantially more advanced clinical development. It helps frame DMD evidence and regulatory risk, but its stage and technology make it an unsuitable like-for-like valuation peer REGENXBIO update.

SLDB

Direct Duchenne development comparator: Solid BioSciences is studying the AAV-delivered SGT-003 gene therapy in clinical trials. Its microdystrophin approach differs from DTIL's gene editing, so trial-safety and enrollment comparisons are more useful than valuation multiples Solid BioSciences Q2 update.